Jefferies Group downgraded shares of Axovant Sciences (NASDAQ:AXON) from a buy rating to a hold rating in a research note released on Thursday, MarketBeat.com reports. Jefferies Group currently has $6.00 price target on the biotechnology company’s stock.
Other research analysts have also issued reports about the stock. Oppenheimer reissued a buy rating and set a $30.00 price target on shares of Axovant Sciences in a research report on Monday, September 25th. HC Wainwright reissued a buy rating and set a $11.00 price target on shares of Axovant Sciences in a research report on Wednesday, September 27th. BidaskClub raised shares of Axovant Sciences from a sell rating to a hold rating in a research report on Thursday, October 5th. Robert W. Baird reissued a hold rating and set a $6.00 price target on shares of Axovant Sciences in a research report on Wednesday, November 1st. Finally, Zacks Investment Research lowered shares of Axovant Sciences from a buy rating to a hold rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $14.18.
Axovant Sciences (NASDAQ:AXON) opened at $4.97 on Thursday. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 12-month low of $4.60 and a 12-month high of $27.98. The firm has a market cap of $555.78, a PE ratio of -2.16 and a beta of 0.06.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.